suspension levels have not changed since 1998. Other industrial countries have gradually reduced their lead exposure and action levels to the point where the exposure, action and suspension levels set by UK regulations are now above those of many other industrial countries.
Lead and lead alloys have a wide range of industrial applications including manufacturing, chemical and construction industries as well as advanced technologies.
Lead is mainly absorbed via inhalation and ingestion. Once absorbed, it is widely distributed and can be found in many tissues. Bones are the main reservoir of lead and carry almost 90% of the body burden in adults. The half-life of lead in the blood stream is believed to be 35 days on average although this is largely affected by the duration of exposure and balance between the blood and bone content.
Many organs can be affected by lead ( Table 1 ). The spectrum of effects ranges from classical toxicity associated with high-level exposure to subtle adverse effects seen in chronic lower level exposure with long latency producing a detectable or clinically significant adverse impact. The literature on lead toxicity should be interpreted cautiously because of various methodological factors including confounding, sample size, method of assessment and others.
Notably, the American National Health and Nutrition Examination Surveys (NHANES) have consistently demonstrated increased mortality associated with lead exposure. For instance, Schober et al. [2] reported that based on NHANES III, the mortality from all cause cardiovascular disease and cancer was increased by 59, 55 and 69% in people with blood lead levels (BLL) over 10 mg/dl as opposed to people with BLL of ,5 mg/dl. Alarmingly even populations with BLL between 5 and 9 mg/dl had higher mortality than populations with BLL ,5 mg/dl.
In order to protect the health of the exposed workers, two main steps are to be considered. The first step is to minimize the exposure by applying risk management principles. This includes elimination (e.g. removing tetraethyl lead from fuel) and substitution (e.g. replacing lead with other elements in paint), using sophisticated engineering methods to enclose and ventilate where lead work is carried out and finally using appropriate personal protective equipment (PPE). In parallel, workers should be informed of the risk and educated how to minimize it.
If risk continues to exist, i.e. the worker is still significantly exposed to lead, then health surveillance should be considered as the second step. The purpose of health surveillance is utilizing a validated technique with sufficient sensitivity to detect early signs of ill-health caused by lead to allow prompt and appropriate reaction.
Health surveillance for lead includes obtaining the medical history and physical examination, biological monitoring (blood or urinary lead level) and biological effect monitoring (haemoglobin, zinc protoporphyrin and delta-aminolevulinic acid dehydratase activity). The direct conclusion of health surveillance is whether the worker is 'fit' to continue working with lead or needs to be removed to avoid further exposure.
In order to make health surveillance programmes successful, two major issues need to be addressed; what is a 'safe' exposure limit that would determine when the health surveillance programme should be instigated and secondly identifying a 'safe' threshold for biological markers above which a specific action should be undertaken.
In order to calculate an exposure limit, policymakers usually use statistical analyses such as regression to find an ambient lead level below which most exposed workers are likely to have BLL (or other defined biological markers) below the safe threshold. The correlation between ambient lead concentration and BLL has been subject to numerous evaluations but the conclusion varies considerably from a strong relationship to none at all. While some of this diversity can be explained by applying different methodologies, it appears that many factors can affect such a relationship including type of industry, size of the particles, personal hygiene, habits (diet, smoking, drinking and nail biting), gender and ethnicity.
Another major determinant of setting an exposure limit is the technical boundaries. This includes availability of advanced engineering methods, the actual impact of implementing such technologies in reducing the ambient lead by a reasonable margin and more importantly in the current economic climate, the cost-effectiveness of developing and implementing such methods. These challenges may explain the discrepancy in exposure limits (and biological threshold as discussed later) set by different countries and agencies. Based on CLAW 2002, the UK exposure limit is set at 150 mg/m 3 with the caveat that health surveillance should start at 75 mg/m 3 which is greater than the threshold suggested by American and some European countries. The United States Occupational Safety & Health Administration [3] mandates a programme of biological monitoring and medical surveillance for all employees exposed to levels of inorganic lead above the action level of 30 mg/m 3 timeweighted average for .30 days/year with a maximum permissible airborne level of 50 mg/m 3 . In Germany [4] , lead has been assigned a MAK (Maximale Arbeitsplatzkonzentrationen) of 100 mg/m 3 . The EU Scientific Committee on Occupational Exposure Limits [5] (SCOEL) recommended airborne exposure of 100 mg/m 3 in 2002. Similarly, setting a biological marker threshold which is safe and simultaneously achievable has proven challenging. Firstly, a reliable biological marker should be identified. Currently, BLL is the gold standard indicator of acute exposure but it cannot be reliably used in assessing chronic and long-term exposure. In contrast, bones are the main pool of lead burden and therefore act as a 'dosimeter' for chronic or accumulative exposure. K-shell X-ray fluorescence technique [6] provides an in vivo measurement of lead in bone; however, it is not yet widely available. Alternatively, cumulative blood lead index [7] has been developed that incorporates BLL and the duration of exposure together and has been demonstrated to have a linear relationship with bone content. It can therefore be considered as a substitute marker for chronic and cumulative exposure.
Secondly, there has been a constant debate whether a safe biological lead threshold can be identified at all. While some of the classic features of lead toxicity are attributed to high exposure levels (with BLL .80-100 mg/dl), many others have been reported to have occurred at BLL ,50 and ,60 mg/dl that are, respectively, the action and suspension levels based on the UK regulations. In the USA, workers with BLL .50 mg/dl should be removed from further exposure.
The EU SCOEL [5] recommended a biological limit value of 30 mg/dl in 2002 and it was suggested [8] that the member states would agree on a suspension level between 40 and 50 mg/dl although such a directive or at least updated recommendation has not yet been published. Some other European countries have already set lower suspension levels. In Australia, medical removal applies for levels $50 mg/dl.
More recent studies especially in ageing populations speculate that chronic exposure to lead can be associated with a number of adverse health impacts, most notably high blood pressure, cardiovascular diseases and cognitive impairment. This is an important issue as the accumulation of doses, which on a solitary basis could be below levels that historically were considered safe, has been implicated in these studies.
The Association for Occupational and Environmental Clinics sponsored a panel of experts who in 2007 published a monograph [9] consisting of five articles discussing various aspects of lead toxicity including historic challenges in setting safe standards, epidemiologic studies of the health effects of lead in adults and also two systematic reviews in respect to the effect of chronic lead exposure on cardiovascular and central nervous systems. Table 2 is reproduced from one of their articles and categorises the health risk associated with BLL intervals. The authors cautioned that the intervals are subject to variation taking into account the individual susceptibility determinants such as existing ill-health, dietary deficiencies, age and genetic polymorphism. They recommended lowering the 'removal' threshold to ,20 mg/dl and ,200-400 mg-years/dl (equivalent to an average BLL of 20 mg/dl for 10-20 years or of 10 mg/dl for 20-40 years) to, respectively, prevent the acute and chronic effects of lead on health.
If lower airborne and blood levels are to be introduced and enforced in the occupational setting, more advanced engineering methods and tighter use of PPE such as respirators are likely to be required. This will surely raise concern over feasibility and practicality at one end and cost-effectiveness at the other and therefore requires collaborative assessment by all stakeholders.
In conclusion, appointed doctors are encouraged to consider the following:
• Reminding lead workers of the importance of hygiene and smoking cessation • Applying clinical judgement in requesting more frequent surveillance including physical examination and biological monitoring • Urging employers to voluntarily reduce lead exposure and action levels • Recommending temporary reduction in exposure at BLL below the legal suspension level in workers with long-term exposure to lead and coexisting ill-health such as hypertension, renal impairment, neurocognitive disorders and risk factors for cardiovascular diseases.
It is also suggested that responsible authorities in the UK, such as the Health & Safety Executive, consider convening a panel comprising of medical, hygiene and industrial experts among others that can be tasked with reviewing the existing and emerging evidence and making recommendations to the policymakers.
